TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27677100

Group type: COMPARATOR
Intervention: 1.5 mL of methylprednisolone (40 mg/mL) and 1.5 mL of 2% lidocaine with 0.5 mL of saline (Group S)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3 mL of leukocyte‐free PRP with 0.5 mL of calcium chloride (Group P)
Number of subjects: 40
Study: 26400966

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (30 g of whey protein daily)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo (2.1 g protein daily)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Both groups (Whey protein and Placebo)
Number of subjects: 196
Study: 23332435

Group type: EXPERIMENTAL
Intervention: Rough-surfaced microthreaded implants
Number of subjects: 34

Group type: COMPARATOR
Intervention: Machined-neck implants
Number of subjects: 34
Study: 21690317

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch (open-label trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine transdermal patch (placebo-controlled trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined data from both trials
Number of subjects: 0
Study: 19068562

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study: 16847405

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) plus stavudine (d4T)
Number of subjects: 509
Study: 12742979

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Tolvaptan 45 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Tolvaptan 60 mg
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 11078176

Group type: EXPERIMENTAL
Intervention: Random spot urinary albumin creatinine ratio (ACR) >30 mg/g
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Increased ACR
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: ACR in men with LVH
Number of subjects: 109
Study: 8764904

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1458788

Group type: EXPERIMENTAL
Intervention: 3 oral pulses of 100 mg prednisolone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 intravenous pulses of 1000 mg methylprednisolone (MP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No corticosteroid treatment (control group)
Number of subjects: 30
Study: 6148470

Group type: EXPERIMENTAL
Intervention: Acyclovir 10 mg/kg 8-hourly for 10 days
Number of subjects: 127

Group type: COMPARATOR
Intervention: Vidarabine 15 mg/kg daily for 10 days
Number of subjects: 127
Study: 31427204

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1096

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1096
Study: 29875287

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (Group A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conservative follow-up (Group B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 52
Study: 28245790

Group type: EXPERIMENTAL
Intervention: History of coronary heart disease (CHD)
Number of subjects: 254

Group type: COMPARATOR
Intervention: No history of coronary heart disease (non-CHD)
Number of subjects: 254
Study: 26141495

Group type: EXPERIMENTAL
Intervention: Antimicrobial surgical glove
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-antimicrobial surgical glove
Number of subjects: 16
Study: 23381484

Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy
Number of subjects: 40
Study: 21085467

Group type: EXPERIMENTAL
Intervention: Intermittent application of Zanzarin (plant-based repellent) twice daily for one week every second week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent application of Zanzarin every fourth week for one week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cohort (no application of repellent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent application of Zanzarin (cohort A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent application of Zanzarin (cohort B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cohort (cohort C)
Number of subjects: 0
Study: 18434457

Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine 1%
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenous meperidine/diazepam
Number of subjects: 48
Study: 17472039

Group type: EXPERIMENTAL
Intervention: Sonicare toothbrush (SC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Manual toothbrush (MTB)
Number of subjects: 61
Study: 12897359

Group type: EXPERIMENTAL
Intervention: Shared care programme
Number of subjects: 248
Study: 10953658

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 0
Study: 9323816

Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuits (bolus heparin dose reduced by 25% to 225 IU/kg, ACT limit 300 sec)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuits
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (noncoated CPB sets, normal heparinization with bolus 300 IU/kg)
Number of subjects: 14
Study: 7903137

Group type: EXPERIMENTAL
Intervention: Transfusion of whole blood tested negative for HIV antibodies
Number of subjects: 116

Group type: COMPARATOR
Intervention: Treatment for malaria and hookworm alone (no transfusion)
Number of subjects: 116
Study: 3839991

Group type: EXPERIMENTAL
Intervention: 0.8 mg intrathecal morphine preoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous papaveretum peroperatively
Number of subjects: 0
Study: 30902428

Group type: EXPERIMENTAL
Intervention: Smartphone application for weight loss
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29959765

Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 71

Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 71
Study: 27072050

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 111

Group type: COMPARATOR
Intervention: Filgrastim
Number of subjects: 111
Study: 24217336

Group type: EXPERIMENTAL
Intervention: Problem-solving education (PSE)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 122
Study: 22074464

Group type: EXPERIMENTAL
Intervention: Visian Implantable Collamer Lens (ICL) implantation
Number of subjects: 63

Group type: COMPARATOR
Intervention: Wavefront-guided laser epithelial keratomileusis (WFG-LASEK)
Number of subjects: 63
Study: 20520284

Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 123
Study: 18801964

Group type: EXPERIMENTAL
Intervention: Fat-adapt
Number of subjects: 8

Group type: COMPARATOR
Intervention: HCHO
Number of subjects: 8
Study: 16160211

Group type: EXPERIMENTAL
Intervention: Magnifier scale
Number of subjects: 790

Group type: COMPARATOR
Intervention: Standard rating scale (SRS)
Number of subjects: 790
Study: 12867218

Group type: EXPERIMENTAL
Intervention: IM olanzapine 10 mg
Number of subjects: 311

Group type: COMPARATOR
Intervention: IM haloperidol 7.5 mg
Number of subjects: 311

Group type: COMPARATOR
Intervention: PO haloperidol (5-20 mg/d)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: PO olanzapine (5-20 mg/d)
Number of subjects: 311
Study: 10394281

Group type: COMPARATOR
Intervention: Exercises and manipulation in patients with acute low back pain (0-4 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Graded exercise program and workplace visits in patients with subacute low back pain (4-12 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exercises in patients with chronic low back pain (>12 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Manipulation in patients with chronic low back pain (>12 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Different exercise regimens in patients with chronic low back pain (>12 weeks)
Number of subjects: 18
Study: 8027280

Group type: EXPERIMENTAL
Intervention: High FSH group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal FSH group
Number of subjects: 48
Study: 2644534

Group type: EXPERIMENTAL
Intervention: Experimental treatment (two-week hospitalization with continuous insulin infusion by external artificial pancreas)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control treatment (NPH insulin, 1 U per kg body weight per day, in two divided doses)
Number of subjects: 26
Study: 789852

Group type: EXPERIMENTAL
Intervention: Folic acid (2 mg twice daily for 30 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30926576

Group type: EXPERIMENTAL
Intervention: PMERT (postmastectomy highly conformal electron radiation therapy with bolus)
Number of subjects: 807

Group type: COMPARATOR
Intervention: PMPhRT (postmastectomy highly conformal photon radiation therapy without bolus)
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: PMERT
Number of subjects: 807

Group type: COMPARATOR
Intervention: PMPhRT
Number of subjects: 807
Study: 28806338

Group type: EXPERIMENTAL
Intervention: Deprivation of CI1 during a 4-week adaptation period after CI2 activation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continued use of CI1 during a 4-week adaptation period after CI2 activation
Number of subjects: 16
Study: 25711330

Group type: EXPERIMENTAL
Intervention: COPD prevalence in HIV-positive adults
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Age and pack-years of smoking
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Region effect on FEV1:FVC ratio
Number of subjects: 1026
Study: 23826890

Group type: EXPERIMENTAL
Intervention: Herbal preparation of myrrh, chamomile extract, and coffee charcoal
Number of subjects: 96

Group type: COMPARATOR
Intervention: Mesalazine
Number of subjects: 96
Study: 20499304

Group type: EXPERIMENTAL
Intervention: Sapylin combined with chemotherapy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study: 18611338

Group type: EXPERIMENTAL
Intervention: Orotracheal intubation (OTI) with GlideScope video laryngoscope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nasotracheal intubation (NTI) with GlideScope video laryngoscope
Number of subjects: 60
Study: 16669964

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg o.d. plus aspirin 325 mg o.d.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg b.d. plus aspirin 325 mg o.d.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo plus aspirin 325 mg o.d.
Number of subjects: 100
Study: 12756159

Group type: EXPERIMENTAL
Intervention: Combined preoperative and intraoperative methylprednisolone (30 mg/kg 4 hours before bypass and in bypass prime)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intraoperative methylprednisolone only (30 mg/kg)
Number of subjects: 29
Study: 11205676

Group type: EXPERIMENTAL
Intervention: Two-dimensional phantoms used in the first round of audit visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water-filled three-dimensional phantom
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phantom for assessing dose in the junction region
Number of subjects: 0
Study: 9183308

Group type: EXPERIMENTAL
Intervention: d-Fenfluramine 15 mg twice daily for 12 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High compliance with the drug regimen
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Positive family history of obesity
Number of subjects: 48
Study: 1554631

Group type: EXPERIMENTAL
Intervention: Washing with water alone
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Washing with soap and water
Number of subjects: 99

Group type: COMPARATOR
Intervention: Not washing
Number of subjects: 99
Study: 3890523

Group type: EXPERIMENTAL
Intervention: Sulfisoxazole therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31088515

Group type: EXPERIMENTAL
Intervention: In2Care® mosquito traps
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29431598

Group type: EXPERIMENTAL
Intervention: M. charantia (2000 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26515411

Group type: EXPERIMENTAL
Intervention: Re-irradiation treatment with a single 8 Gy dose for the worst group identified.
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Worst group identified from the survival prediction model.
Number of subjects: 811
Study: 25325203

Group type: EXPERIMENTAL
Intervention: Single-dose regimen: 1 ciprofloxacin 500 mg tablet and 2 metronidazole 250 mg tablets taken 2 hours before biopsy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Multiple-dose regimen: ciprofloxacin and metronidazole every 12 hours from 3 days before biopsy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Single-dose regimen
Number of subjects: 160

Group type: COMPARATOR
Intervention: Multiple-dose regimen
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 160
Study: 22691922

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS) 43 g daily for 12 weeks
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Corn-soya blend (CSB) 71 g daily for 12 weeks
Number of subjects: 299

Group type: COMPARATOR
Intervention: No supplement (control)
Number of subjects: 299
Study: 20168217

Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty (DALK)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 81
Study: 17613573

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A + additional physiotherapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Botulinum toxin type A
Number of subjects: 38
Study: 16288095

Group type: EXPERIMENTAL
Intervention: 4-arm clinic and home-based intervention using nurse case management and community health workers
Number of subjects: 728
Study: 12399697

Group type: EXPERIMENTAL
Intervention: Cervitec varnish, containing 1% chlorhexidine and 1% thymol; applied on two separate occasions to all tooth surfaces at an interval of 3‐4 days.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Corsodyl gel, containing 1% chlorhexidine; applied for 3 x 5 min in individual applicators on 2 consecutive days.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo varnish; applied on two separate occasions to all tooth surfaces at an interval of 3‐4 days.
Number of subjects: 18
Study: 9950660

Group type: EXPERIMENTAL
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 0
Study: 7555557

Group type: EXPERIMENTAL
Intervention: Low-GI, low-carbohydrate breakfast (41 g carbohydrate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-GI, low-carbohydrate breakfast (41 g carbohydrate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-GI, high-carbohydrate breakfast (84 g carbohydrate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-GI, high-carbohydrate breakfast (84 g carbohydrate)
Number of subjects: 8
Study: 1873936

Group type: EXPERIMENTAL
Intervention: Normal protein diet (1.1 +/- 0.3 g/kg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low protein diet (0.7 +/- 0.1 g/kg/day)
Number of subjects: 24
Study: 6352788

Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 51
Study: 30419989

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (20-50 mg/d)
Number of subjects: 552
Study: 29631444

Group type: EXPERIMENTAL
Intervention: Bicycle train intervention (BTI)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study: 26809842

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg day-1
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 25304843

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 22414837

Group type: EXPERIMENTAL
Intervention: Ultrasonic mixing method
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional mixing method
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Trituration mixing method
Number of subjects: 60
Study: 19906761

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² plus Epirubicin 75 mg/m² (DE)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² plus Capecitabine 950 mg/m² (DC)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Docetaxel plus Epirubicin (DE)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Docetaxel plus Capecitabine (DC)
Number of subjects: 272
Study: 17915035

Group type: EXPERIMENTAL
Intervention: Exercise-only group (3 sessions of 60 minutes per week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise and cognitive training group (2 sessions of 60 minutes exercise and 1 session of 60 minutes cognitive training per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-training control group (contacted every 4 weeks)
Number of subjects: 0
Study: 16157124

Group type: EXPERIMENTAL
Intervention: 17‐alpha hydroxyprogesterone caproate (17‐OHP caproate)
Number of subjects: 459
Study: 12174530

Group type: EXPERIMENTAL
Intervention: Structured physical activities (formal)
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Unstructured physical activities (nonformal)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Sedentary group
Number of subjects: 594

Group type: COMPARATOR
Intervention: Low activity group
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Formal physical activities
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Informal physical activities
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Physical activity groups (girls)
Number of subjects: 594
Study: 9974404

Group type: EXPERIMENTAL
Intervention: Factor VIIa generation in the pericardium
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prothrombin F1+2 levels in the pericardium
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Thrombin-antithrombin (TAT) levels in the pericardium
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Correlation of factor VIIa, F1+2, and TAT levels
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Heparin levels
Number of subjects: 12
Study: 7588500

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS) consumed occasionally (once a week)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS) consumed regularly (every day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of breath hydrogen excretion between occasional and regular consumption of FOS
Number of subjects: 14
Study: 2298594

Group type: EXPERIMENTAL
Intervention: Support group attendance (n = 25)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Bedside support from nurses and health professionals (n = 30)
Number of subjects: 55
Study: 344088

Group type: EXPERIMENTAL
Intervention: Naproxen 750 mg daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Naproxen 500 to 750 mg daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Indomethacin 75 mg daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acetylsalicylic acid 1500 mg daily
Number of subjects: 120
Study: 31285303

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1231
Study: 28411872

Group type: EXPERIMENTAL
Intervention: 200 mg risankizumab
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 600 mg risankizumab
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: risankizumab (pooled 200 mg and 600 mg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: risankizumab (all doses)
Number of subjects: 121
Study: 26640708

Group type: EXPERIMENTAL
Intervention: Orthopedic Manual Therapy (OMT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dry Needling and Stretching (DN-S)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Soft Tissue Techniques (STT)
Number of subjects: 36
Study: 23702498

Group type: EXPERIMENTAL
Intervention: Ultrasound guided platelets rich plasma (PRP) injection and conservative treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional conservative treatment only
Number of subjects: 30
Study: 22334465

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 19335746

Group type: EXPERIMENTAL
Intervention: ET receptor antagonists (ETRAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective ET(A) blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonselective ET(A)/ET(B) blockade
Number of subjects: 0
Study: 17615011

Group type: EXPERIMENTAL
Intervention: Fluoride gel
Number of subjects: 0
Study: 15156869

Group type: EXPERIMENTAL
Intervention: Ozonated autohemotherapy (50 microg/mL ozone)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (autohemotherapy with exposure to oxygen)
Number of subjects: 12
Study: 11418308

Group type: EXPERIMENTAL
Intervention: Vaccines (3 weekly injections, followed by monthly injections for 5 months)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Vaccines
Number of subjects: 69
Study: 9554348

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8147523

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Laryngeal mask without insertion aid
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Laryngeal mask with insertion aid
Number of subjects: 150
Study: 2905145

Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg kg‐1
Number of subjects: 57

Group type: COMPARATOR
Intervention: Vecuronium 0.06 mg kg‐1
Number of subjects: 57
Study: 29726802

Group type: EXPERIMENTAL
Intervention: Posterior decompression and fixation with OKA ≤ 23° (group U)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Posterior decompression and fixation with OKA > 23° (group O)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Posterior decompression and fixation (both groups)
Number of subjects: 20
Study: 27404222

Group type: EXPERIMENTAL
Intervention: Avoidance of arterial hyperoxemia during CPB
Number of subjects: 298

Group type: COMPARATOR
Intervention: Usual care during CPB
Number of subjects: 298